Alexandre Lebeaut also set to be chief scientific officer
Ipsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s strategy to address unmet medical needs.
Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed interim head of R&D in December 2016.
Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.
David Meek, CEO of Ipsen, said: “Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies.
“During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programmes.
“He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”